Search

Your search keyword '"Jensen, Thomas S."' showing total 29 results
Start Over Author "Jensen, Thomas S."
29 results on '"Jensen, Thomas S."'

1. Heterogeneity of treatment effect of higher dose dexamethasone by geographic region (Europe vs. India) in patients with COVID-19 and severe hypoxemia – a post hoc evaluation of the COVID STEROID 2 trial

Author

Munch, Marie W., Myatra, Sheila N., Tirupakuzhi Vijayaraghavan, Bharath Kumar, Saseedharan, Sanjith, Benfield, Thomas, Wahlin, Rebecka R., Rasmussen, Bodil S., Andreasen, Anne Sofie, Poulsen, Lone M., Cioccari, Luca, Khan, Mohd S., Kapadia, Farhad, Divatia, Jigeeshu V., Brøchner, Anne C., Bestle, Morten H., Helleberg, Marie, Michelsen, Jens, Padmanaban, Ajay, Bose, Neeta, Møller, Anders, Borawake, Kapil, Kristiansen, Klaus T., Shukla, Urvi, Chew, Michelle S., Dixit, Subhal, Ulrik, Charlotte S., Amin, Pravin R., Chawla, Rajesh, Wamberg, Christian A., Shah, Mehul S., Darfelt, Iben S., Jørgensen, Vibeke L., Smitt, Margit, Granholm, Anders, Kjær, Maj-Brit N., Møller, Morten H., Meyhoff, Tine S., Vesterlund, Gitte K., Hammond, Naomi E., Micallef, Sharon, Bassi, Abhinav, John, Oommen, Jha, Anubhuti, Cronhjort, Maria, Jakob, Stephan M., Gluud, Christian, Lange, Theis, Kadam, Vaijayanti, Marcussen, Klaus V., Hollenberg, Jacob, Hedman, Anders, Nielsen, Henrik, Schjørring, Olav L., Jensen, Marie Q., Leistner, Jens W., Jonassen, Trine B., Kristensen, Camilla M., Clapp, Esben C., Hjortsø, Carl J.S., Jensen, Thomas S., Halstad, Liv S., Bak, Emilie R.B., Zaabalawi, Reem, Metcalf-Clausen, Matias, Abdi, Suhayb, Hatley, Emma V., Aksnes, Tobias S., Gleipner-Andersen, Emil, Alarcón, A.Felix, Yamin, Gabriel, Heymowski, Adam, Berggren, Anton, la Cour, Kirstine, Weihe, Sarah, Pind, Alison H., Engstrøm, Janus, Jha, Vivekanand, Venkatesh, Balasubramanian, Perner, Anders, Hammond, Naomi, Munch, Marie Warrer, and Møller, Morten Hylander

Published
2024
Full Text
View/download PDF

2. Heterogeneity of treatment effect of higher dose dexamethasone by geographic region (Europe vs. India) in patients with COVID-19 and severe hypoxemia – a post hoc evaluation of the COVID STEROID 2 trial

Author

Tirupakuzhi Vijayaraghavan, Bharath Kumar, primary, Granholm, Anders, additional, Myatra, Sheila N., additional, Jha, Vivekanand, additional, Hammond, Naomi, additional, Micallef, Sharon, additional, Munch, Marie Warrer, additional, Kjær, Maj-Brit N., additional, Møller, Morten Hylander, additional, Lange, Theis, additional, Perner, Anders, additional, Venkatesh, Balasubramanian, additional, Munch, Marie W., additional, Tirupakuzhi Vijayaraghavan, Bharath Kumar, additional, Saseedharan, Sanjith, additional, Benfield, Thomas, additional, Wahlin, Rebecka R., additional, Rasmussen, Bodil S., additional, Andreasen, Anne Sofie, additional, Poulsen, Lone M., additional, Cioccari, Luca, additional, Khan, Mohd S., additional, Kapadia, Farhad, additional, Divatia, Jigeeshu V., additional, Brøchner, Anne C., additional, Bestle, Morten H., additional, Helleberg, Marie, additional, Michelsen, Jens, additional, Padmanaban, Ajay, additional, Bose, Neeta, additional, Møller, Anders, additional, Borawake, Kapil, additional, Kristiansen, Klaus T., additional, Shukla, Urvi, additional, Chew, Michelle S., additional, Dixit, Subhal, additional, Ulrik, Charlotte S., additional, Amin, Pravin R., additional, Chawla, Rajesh, additional, Wamberg, Christian A., additional, Shah, Mehul S., additional, Darfelt, Iben S., additional, Jørgensen, Vibeke L., additional, Smitt, Margit, additional, Møller, Morten H., additional, Meyhoff, Tine S., additional, Vesterlund, Gitte K., additional, Hammond, Naomi E., additional, Bassi, Abhinav, additional, John, Oommen, additional, Jha, Anubhuti, additional, Cronhjort, Maria, additional, Jakob, Stephan M., additional, Gluud, Christian, additional, Kadam, Vaijayanti, additional, Marcussen, Klaus V., additional, Hollenberg, Jacob, additional, Hedman, Anders, additional, Nielsen, Henrik, additional, Schjørring, Olav L., additional, Jensen, Marie Q., additional, Leistner, Jens W., additional, Jonassen, Trine B., additional, Kristensen, Camilla M., additional, Clapp, Esben C., additional, Hjortsø, Carl J.S., additional, Jensen, Thomas S., additional, Halstad, Liv S., additional, Bak, Emilie R.B., additional, Zaabalawi, Reem, additional, Metcalf-Clausen, Matias, additional, Abdi, Suhayb, additional, Hatley, Emma V., additional, Aksnes, Tobias S., additional, Gleipner-Andersen, Emil, additional, Alarcón, A.Felix, additional, Yamin, Gabriel, additional, Heymowski, Adam, additional, Berggren, Anton, additional, la Cour, Kirstine, additional, Weihe, Sarah, additional, Pind, Alison H., additional, and Engstrøm, Janus, additional

Published
2023
Full Text
View/download PDF

4. Line shape analysis of the Kβ transition in muonic hydrogen

Author

Covita, Daniel S., Anagnostopoulos, Dimitrios F., Fuhrmann, Hermann, Gorke, Hubert, Gotta, Detlev, Gruber, Alexander, Hirtl, Albert, Ishiwatari, Tomoichi, Indelicato, Paul, Jensen, Thomas S., Le Bigot, Eric-Olivier, Markushin, Valeri E., Nekipelov, Michael, Pomerantsev, Vladimir N., Popov, Vladimir P., dos Santos, Joaquim M. F., Schmid, Philipp, Simons, Leopold M., Theisen, Marian, Trassinelli, Martino, Veloso, Joao F. C. A., and Zmeskal, Johann

Published
2018
Full Text
View/download PDF

5. Restriction of Intravenous Fluid in ICU Patients with Septic Shock

Author

Meyhoff, Tine S., Hjortrup, Peter B., Wetterslev, Jørn, Sivapalan, Praleene, Laake, Jon H., Cronhjort, Maria, Jakob, Stephan M., Cecconi, Maurizio, Nalos, Marek, Ostermann, Marlies, Malbrain, Manu, Pettilä, Ville, Møller, Morten H., Kjær, Maj-Brit N., Lange, Theis, Overgaard-Steensen, Christian, Brand, Björn A., Winther-Olesen, Marie, White, Jonathan O., Quist, Lars, Westergaard, Bo, Jonsson, Andreas B., Hjortsø, Carl J.S., Meier, Nick, Jensen, Thomas S., Engstrøm, Janus, Nebrich, Lars, Andersen-Ranberg, Nina C., Jensen, Jacob V., Joseph, Neeliya A., Poulsen, Lone M., Herløv, Louise S., Sølling, Christoffer G., Pedersen, Susan K., Knudsen, Kurt K., Straarup, Therese S., Vang, Marianne L., Bundgaard, Helle, Rasmussen, B. S., Aagaard, S. R., Hildebrandt, Thomas, Russell, Lene, Bestle, Morten H., Schønemann-Lund, Martin, Brøchner, Anne C., Elvander, Claes F., Hoffmann, Søren K.L., Rasmussen, Michael L., Martin, Yvonne K., Friberg, Fredrik F., Seter, Herman, Aslam, Tayyba N., Ådnøy, Sigrid, Seidel, Philipp, Strand, Kristian, Johnstad, Bror, Joelsson-Alm, Eva, Christensen, Jens, Ahlstedt, Christian, Pfortmueller, Carmen A., Siegemund, Martin, Greco, Massimiliano, Raděj, Jaroslav, Kříž, Miroslav, Gould, Doug W., Rowan, Kathy M., Mouncey, Paul R., Perner, Anders, Siegumfeldt, Rine Moulvad, and Vestergaard, Stine Rom

Subjects
PROTOCOL, Adult, SEPSIS, RESUSCITATION, MORTALITY, Critical Care/methods, ADULTS, General Medicine, Intensive Care Units, TRIALS, MANAGEMENT, Humans, Administration, Intravenous, 610 Medicine & health, Shock, Septic/mortality, Fluid Therapy/adverse effects
Abstract

BACKGROUND: Intravenous fluids are recommended for the treatment of patients who are in septic shock, but higher fluid volumes have been associated with harm in patients who are in the intensive care unit (ICU).METHODS: In this international, randomized trial, we assigned patients with septic shock in the ICU who had received at least 1 liter of intravenous fluid to receive restricted intravenous fluid or standard intravenous fluid therapy; patients were included if the onset of shock had been within 12 hours before screening. The primary outcome was death from any cause within 90 days after randomization.RESULTS: We enrolled 1554 patients; 770 were assigned to the restrictive-fluid group and 784 to the standard-fluid group. Primary outcome data were available for 1545 patients (99.4%). In the ICU, the restrictive-fluid group received a median of 1798 ml of intravenous fluid (interquartile range, 500 to 4366); the standard-fluid group received a median of 3811 ml (interquartile range, 1861 to 6762). At 90 days, death had occurred in 323 of 764 patients (42.3%) in the restrictive-fluid group, as compared with 329 of 781 patients (42.1%) in the standard-fluid group (adjusted absolute difference, 0.1 percentage points; 95% confidence interval [CI], -4.7 to 4.9; P = 0.96). In the ICU, serious adverse events occurred at least once in 221 of 751 patients (29.4%) in the restrictive-fluid group and in 238 of 772 patients (30.8%) in the standard-fluid group (adjusted absolute difference, -1.7 percentage points; 99% CI, -7.7 to 4.3). At 90 days after randomization, the numbers of days alive without life support and days alive and out of the hospital were similar in the two groups.CONCLUSIONS: Among adult patients with septic shock in the ICU, intravenous fluid restriction did not result in fewer deaths at 90 days than standard intravenous fluid therapy. (Funded by the Novo Nordisk Foundation and others; CLASSIC ClinicalTrials.gov number, NCT03668236.).

Published
2022

6. Restriction of Intravenous Fluid in ICU Patients with Septic Shock

Author

Meyhoff, Tine S., primary, Hjortrup, Peter B., additional, Wetterslev, Jørn, additional, Sivapalan, Praleene, additional, Laake, Jon H., additional, Cronhjort, Maria, additional, Jakob, Stephan M., additional, Cecconi, Maurizio, additional, Nalos, Marek, additional, Ostermann, Marlies, additional, Malbrain, Manu, additional, Pettilä, Ville, additional, Møller, Morten H., additional, Kjær, Maj-Brit N., additional, Lange, Theis, additional, Overgaard-Steensen, Christian, additional, Brand, Björn A., additional, Winther-Olesen, Marie, additional, White, Jonathan O., additional, Quist, Lars, additional, Westergaard, Bo, additional, Jonsson, Andreas B., additional, Hjortsø, Carl J.S., additional, Meier, Nick, additional, Jensen, Thomas S., additional, Engstrøm, Janus, additional, Nebrich, Lars, additional, Andersen-Ranberg, Nina C., additional, Jensen, Jacob V., additional, Joseph, Neeliya A., additional, Poulsen, Lone M., additional, Herløv, Louise S., additional, Sølling, Christoffer G., additional, Pedersen, Susan K., additional, Knudsen, Kurt K., additional, Straarup, Therese S., additional, Vang, Marianne L., additional, Bundgaard, Helle, additional, Rasmussen, Bodil S., additional, Aagaard, Søren R., additional, Hildebrandt, Thomas, additional, Russell, Lene, additional, Bestle, Morten H., additional, Schønemann-Lund, Martin, additional, Brøchner, Anne C., additional, Elvander, Claes F., additional, Hoffmann, Søren K.L., additional, Rasmussen, Michael L., additional, Martin, Yvonne K., additional, Friberg, Fredrik F., additional, Seter, Herman, additional, Aslam, Tayyba N., additional, Ådnøy, Sigrid, additional, Seidel, Philipp, additional, Strand, Kristian, additional, Johnstad, Bror, additional, Joelsson-Alm, Eva, additional, Christensen, Jens, additional, Ahlstedt, Christian, additional, Pfortmueller, Carmen A., additional, Siegemund, Martin, additional, Greco, Massimiliano, additional, Raděj, Jaroslav, additional, Kříž, Miroslav, additional, Gould, Doug W., additional, Rowan, Kathy M., additional, Mouncey, Paul R., additional, and Perner, Anders, additional

Published
2022
Full Text
View/download PDF

7. Atomic Cascade and Precision Physics with Light Muonic and Hadronic Atoms

Author

Jensen, Thomas S., Markushin, Valeri E., Beig, R., editor, Englert, G., editor, Frisch, U., editor, Hänggi, P., editor, Hepp, K., editor, Hillebrandt, W., editor, Imboden, D., editor, Jaffe, R. L., editor, Lipowsky, R., editor, v. Löhneysen, H., editor, Ojima, I., editor, Sornette, D., editor, Theisen, S., editor, Weise, W., editor, Wess, J., editor, Zittartz, J., editor, Karshenboim, S. G., editor, and Smirnov, Valery B., editor

Published
2003
Full Text
View/download PDF

8. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia:The COVID STEROID 2 Randomized Trial

Author

Munch, Marie W, Myatra, Sheila N, Vijayaraghavan, Bharath Kumar Tirupakuzhi, Saseedharan, Sanjith, Benfield, Thomas, Wahlin, Rebecka R, Rasmussen, Bodil S, Andreasen, Anne Sofie, Poulsen, Lone M, Cioccari, Luca, Khan, Mohd S, Kapadia, Farhad, Divatia, Jigeeshu V, Br��chner, Anne C, Bestle, Morten H, Helleberg, Marie, Michelsen, Jens, Padmanaban, Ajay, Bose, Neeta, M��ller, Anders, Borawake, Kapil, Kristiansen, Klaus T, Shukla, Urvi, Chew, Michelle S, Dixit, Subhal, Ulrik, Charlotte S, Amin, Pravin R, Chawla, Rajesh, Wamberg, Christian A, Shah, Mehul S, Darfelt, Iben S, J��rgensen, Vibeke L, Smitt, Margit, Granholm, Anders, Kj��r, Maj-Brit N, M��ller, Morten H, Meyhoff, Tine S, Vesterlund, Gitte K, Hammond, Naomi E, Micallef, Sharon, Bassi, Abhinav, John, Oommen, Jha, Anubhuti, Cronhjort, Maria, Jakob, Stephan M, Gluud, Christian, Lange, Theis, Kadam, Vaijayanti, Marcussen, Klaus V, Hollenberg, Jacob, Hedman, Anders, Nielsen, Henrik, Schj��rring, Olav L, Jensen, Marie Q, Leistner, Jens W, Jonassen, Trine B, Kristensen, Camilla M, Clapp, Esben C, Hjorts��, Carl J S, Jensen, Thomas S, Halstad, Liv S, Bak, Emilie R B, Zaabalawi, Reem, Metcalf-Clausen, Matias, Abdi, Suhayb, Hatley, Emma V, Aksnes, Tobias S, Gleipner-Andersen, Emil, Alarc��n, Arif F, Yamin, Gabriel, Heymowski, Adam, Berggren, Anton, La Cour, Kirstine, Weihe, Sarah, Pind, Alison H, Engstr��m, Janus, Jha, Vivekanand, Venkatesh, Balasubramanian, and Perner, Anders

Subjects
Dexamethasone/administration & dosage, Male, Mycoses/etiology, medicine.medical_treatment, Dexamethasone, Hypoxemia, law.invention, Randomized controlled trial, law, medicine, Shock, Septic/etiology, Humans, Single-Blind Method, Hypoxia, 610 Medicine & health, Glucocorticoids, Aged, Mechanical ventilation, Dose-Response Relationship, Drug, Septic shock, business.industry, Hypoxia/etiology, COVID-19, Glucocorticoids/administration & dosage, General Medicine, Middle Aged, medicine.disease, Shock, Septic, Respiration, Artificial, COVID-19 Drug Treatment, Life Support Care, Dose–response relationship, Mycoses, Relative risk, Anesthesia, Life support, COVID-19/complications, Female, medicine.symptom, business, medicine.drug
Abstract

Importance A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in patients with severe and critical COVID-19, but a higher dose may benefit those with more severe disease. Objective To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia. Design, Setting, and Participants A multicenter, randomized clinical trial was conducted between August 2020 and May 2021 at 26 hospitals in Europe and India and included 1000 adults with confirmed COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation. End of 90-day follow-up was on August 19, 2021. Interventions Patients were randomized 1:1 to 12 mg/d of intravenous dexamethasone (n���=���503) or 6 mg/d of intravenous dexamethasone (n���=���497) for up to 10 days. Main Outcomes and Measures The primary outcome was the number of days alive without life support (invasive mechanical ventilation, circulatory support, or kidney replacement therapy) at 28 days and was adjusted for stratification variables. Of the 8 prespecified secondary outcomes, 5 are included in this analysis (the number of days alive without life support at 90 days, the number of days alive out of the hospital at 90 days, mortality at 28 days and at 90 days, and ���1 serious adverse reactions at 28 days). Results Of the 1000 randomized patients, 982 were included (median age, 65 [IQR, 55-73] years; 305 [31%] women) and primary outcome data were available for 971 (491 in the 12 mg of dexamethasone group and 480 in the 6 mg of dexamethasone group). The median number of days alive without life support was 22.0 days (IQR, 6.0-28.0 days) in the 12 mg of dexamethasone group and 20.5 days (IQR, 4.0-28.0 days) in the 6 mg of dexamethasone group (adjusted mean difference, 1.3 days [95% CI, 0-2.6 days]; P���=���.07). Mortality at 28 days was 27.1% in the 12 mg of dexamethasone group vs 32.3% in the 6 mg of dexamethasone group (adjusted relative risk, 0.86 [99% CI, 0.68-1.08]). Mortality at 90 days was 32.0% in the 12 mg of dexamethasone group vs 37.7% in the 6 mg of dexamethasone group (adjusted relative risk, 0.87 [99% CI, 0.70-1.07]). Serious adverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% in the 12 mg of dexamethasone group vs 13.4% in the 6 mg of dexamethasone group (adjusted relative risk, 0.83 [99% CI, 0.54-1.29]). Conclusions and Relevance Among patients with COVID-19 and severe hypoxemia, 12 mg/d of dexamethasone compared with 6 mg/d of dexamethasone did not result in statistically significantly more days alive without life support at 28 days. However, the trial may have been underpowered to identify a significant difference. Trial Registration ClinicalTrials.gov Identifier: NCT04509973 and ctri.nic.in Identifier: CTRI/2020/10/028731.

Published
2021

10. Genetic regulation of RNA splicing in human pancreatic islets.

Author

Atla, Goutham, Bonàs-Guarch, Silvia, Cuenca-Ardura, Mirabai, Beucher, Anthony, Crouch, Daniel J. M., Garcia-Hurtado, Javier, Moran, Ignasi, the T2DSystems Consortium, Cnop, Miriam, Eliasson, Lena, Esguerra, Jonathan Lou S., Eizirik, Décio L., Groop, Leif, Jensen, Thomas S., Hansen, Torben, Marchetti, Piero, Mercader, Josep M., Mulder, Hindrik, Stabile-Barnett, Chris R., and Thirion, Christian

Published
2022
Full Text
View/download PDF

11. A genome-wide association study of men with symptoms of testicular dysgenesis syndrome and its network biology interpretation

Author

Dalgaard, Marlene D, Weinhold, Nils, Edsgärd, Daniel, Silver, Jeremy D, Pers, Tune H, Nielsen, John E, Jørgensen, Niels, Juul, Anders, Gerds, Thomas A, Giwercman, Aleksander, Giwercman, Yvonne L, Cohn-Cedermark, Gabriella, Virtanen, Helena E, Toppari, Jorma, Daugaard, Gedske, Jensen, Thomas S, Brunak, Søren, Rajpert-De Meyts, Ewa, Skakkebæk, Niels E, Leffers, Henrik, and Gupta, Ramneek

Published
2012
Full Text
View/download PDF

15. A scored human protein–protein interaction network to catalyze genomic interpretation

Author

Li, Taibo, primary, Wernersson, Rasmus, additional, Hansen, Rasmus B, additional, Horn, Heiko, additional, Mercer, Johnathan, additional, Slodkowicz, Greg, additional, Workman, Christopher T, additional, Rigina, Olga, additional, Rapacki, Kristoffer, additional, Stærfeldt, Hans H, additional, Brunak, Søren, additional, Jensen, Thomas S, additional, and Lage, Kasper, additional

Published
2016
Full Text
View/download PDF

17. A scored human protein–protein interaction network to catalyze genomic interpretation

Author

Li, Taibo, Wernersson, Rasmus, Hansen, Rasmus B, Horn, Heiko, Mercer, Johnathan, Slodkowicz, Greg, Workman, Christopher T, Rigina, Olga, Rapacki, Kristoffer, Stærfeldt, Hans H, Brunak, Søren, Jensen, Thomas S, and Lage, Kasper

Abstract

Genome-scale human protein–protein interaction networks are critical to understanding cell biology and interpreting genomic data, but challenging to produce experimentally. Through data integration and quality control, we provide a scored human protein–protein interaction network (InWeb_InBioMap, or InWeb_IM) with severalfold more interactions (>500,000) and better functional biological relevance than comparable resources. We illustrate that InWeb_InBioMap enables functional interpretation of >4,700 cancer genomes and genes involved in autism.

Published
2017
Full Text
View/download PDF

18. A genome-wide association study of men with symptoms of testicular dysgenesis syndrome and its network biology interpretation

Author

Dalgaard, Marlene D, primary, Weinhold, Nils, additional, Edsgärd, Daniel, additional, Silver, Jeremy D, additional, Pers, Tune H, additional, Nielsen, John E, additional, Jørgensen, Niels, additional, Juul, Anders, additional, Gerds, Thomas A, additional, Giwercman, Aleksander, additional, Giwercman, Yvonne L, additional, Cohn-Cedermark, Gabriella, additional, Virtanen, Helena E, additional, Toppari, Jorma, additional, Daugaard, Gedske, additional, Jensen, Thomas S, additional, Brunak, Søren, additional, Rajpert-De Meyts, Ewa, additional, Skakkebæk, Niels E, additional, Leffers, Henrik, additional, and Gupta, Ramneek, additional

Published
2011
Full Text
View/download PDF

19. Bioinformatics-Driven Identification and Examination of Candidate Genes for Non-Alcoholic Fatty Liver Disease

Author

Banasik, Karina, primary, Justesen, Johanne M., additional, Hornbak, Malene, additional, Krarup, Nikolaj T., additional, Gjesing, Anette P., additional, Sandholt, Camilla H., additional, Jensen, Thomas S., additional, Grarup, Niels, additional, Andersson, Åsa, additional, Jørgensen, Torben, additional, Witte, Daniel R., additional, Sandbæk, Annelli, additional, Lauritzen, Torsten, additional, Thorens, Bernard, additional, Brunak, Søren, additional, Sørensen, Thorkild I. A., additional, Pedersen, Oluf, additional, and Hansen, Torben, additional

Published
2011
Full Text
View/download PDF

20. Quantitative Phosphoproteomics Reveals Widespread Full Phosphorylation Site Occupancy During Mitosis

Author

Olsen, Jesper V., primary, Vermeulen, Michiel, additional, Santamaria, Anna, additional, Kumar, Chanchal, additional, Miller, Martin L., additional, Jensen, Lars J., additional, Gnad, Florian, additional, Cox, Jürgen, additional, Jensen, Thomas S., additional, Nigg, Erich A., additional, Brunak, Søren, additional, and Mann, Matthias, additional

Published
2010
Full Text
View/download PDF

27. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial (vol 326, pg 1807, 2021)

Author

Munch, Marie W., Myatra, Sheila N., Vijayaraghavan, Bharath Kumar Tirupakuzhi, Saseedharan, Sanjith, Benfield, Thomas, Wahlin, Rebecka R., Rasmussen, Bodil S., Andreasen, Anne Sofie, Poulsen, Lone M., Cioccari, Luca, Khan, Mohd S., Kapadia, Farhad, Divatia, Jigeeshu V., Brochner, Anne C., Bestle, Morten H., Helleberg, Marie, Michelsen, Jens, Padmanaban, Ajay, Bose, Neeta, Moller, Anders, Borawake, Kapil, Kristiansen, Klaus T., Shukla, Urvi, Chew, Michelle S., Dixit, Subhal, Ulrik, Charlotte S., Amin, Pravin R., Chawla, Rajesh, Wamberg, Christian A., Shah, Mehul S., Darfelt, Iben S., Jorgensen, Vibeke L., Smitt, Margit, Granholm, Anders, Kjaer, Maj-Brit N., Moller, Morten H., Meyhoff, Tine S., Vesterlund, Gitte K., Hammond, Naomi E., Micallef, Sharon, Bassi, Abhinav, John, Oommen, Jha, Anubhuti, Cronhjort, Maria, Jakob, Stephan M., Christian Gluud, Lange, Theis, Kadam, Vaijayanti, Marcussen, Klaus V., Hollenberg, Jacob, Hedman, Anders, Nielsen, Henrik, Schjorring, Olav L., Jensen, Marie Q., Leistner, Jens W., Jonassen, Trine B., Kristensen, Camilla M., Clapp, Esben C., Hjortso, Carl J. S., Jensen, Thomas S., Halstad, Liv S., Bak, Emilie R. B., Zaabalawi, Reem, Metcalf-Clausen, Matias, Abdi, Suhayb, Hatley, Emma V., Aksnes, Tobias S., Gleipner-Andersen, Emil, Alarcon, Arif F., Yamin, Gabriel, Heymowski, Adam, Berggren, Anton, La Cour, Kirstine, Weihe, Sarah, Pind, Alison H., Engstrom, Janus, Jha, Vivekanand, Venkatesh, Balasubramanian, and Perner, Anders

29. Effect of 12 mg vs 6 mg of Dexamethasone on the Number of Days Alive Without Life Support in Adults With COVID-19 and Severe Hypoxemia: The COVID STEROID 2 Randomized Trial.

Author

Munch MW, Myatra SN, Vijayaraghavan BKT, Saseedharan S, Benfield T, Wahlin RR, Rasmussen BS, Andreasen AS, Poulsen LM, Cioccari L, Khan MS, Kapadia F, Divatia JV, Brøchner AC, Bestle MH, Helleberg M, Michelsen J, Padmanaban A, Bose N, Møller A, Borawake K, Kristiansen KT, Shukla U, Chew MS, Dixit S, Ulrik CS, Amin PR, Chawla R, Wamberg CA, Shah MS, Darfelt IS, Jørgensen VL, Smitt M, Granholm A, Kjær MN, Møller MH, Meyhoff TS, Vesterlund GK, Hammond NE, Micallef S, Bassi A, John O, Jha A, Cronhjort M, Jakob SM, Gluud C, Lange T, Kadam V, Marcussen KV, Hollenberg J, Hedman A, Nielsen H, Schjørring OL, Jensen MQ, Leistner JW, Jonassen TB, Kristensen CM, Clapp EC, Hjortsø CJS, Jensen TS, Halstad LS, Bak ERB, Zaabalawi R, Metcalf-Clausen M, Abdi S, Hatley EV, Aksnes TS, Gleipner-Andersen E, Alarcón AF, Yamin G, Heymowski A, Berggren A, La Cour K, Weihe S, Pind AH, Engstrøm J, Jha V, Venkatesh B, and Perner A

Subjects
Aged, COVID-19 complications, COVID-19 mortality, Dexamethasone adverse effects, Dose-Response Relationship, Drug, Female, Glucocorticoids adverse effects, Humans, Hypoxia etiology, Hypoxia therapy, Male, Middle Aged, Mycoses etiology, Respiration, Artificial, Shock, Septic etiology, Single-Blind Method, Dexamethasone administration & dosage, Glucocorticoids administration & dosage, Life Support Care, COVID-19 Drug Treatment
Abstract

Importance: A daily dose with 6 mg of dexamethasone is recommended for up to 10 days in patients with severe and critical COVID-19, but a higher dose may benefit those with more severe disease., Objective: To assess the effects of 12 mg/d vs 6 mg/d of dexamethasone in patients with COVID-19 and severe hypoxemia., Design, Setting, and Participants: A multicenter, randomized clinical trial was conducted between August 2020 and May 2021 at 26 hospitals in Europe and India and included 1000 adults with confirmed COVID-19 requiring at least 10 L/min of oxygen or mechanical ventilation. End of 90-day follow-up was on August 19, 2021., Interventions: Patients were randomized 1:1 to 12 mg/d of intravenous dexamethasone (n = 503) or 6 mg/d of intravenous dexamethasone (n = 497) for up to 10 days., Main Outcomes and Measures: The primary outcome was the number of days alive without life support (invasive mechanical ventilation, circulatory support, or kidney replacement therapy) at 28 days and was adjusted for stratification variables. Of the 8 prespecified secondary outcomes, 5 are included in this analysis (the number of days alive without life support at 90 days, the number of days alive out of the hospital at 90 days, mortality at 28 days and at 90 days, and ≥1 serious adverse reactions at 28 days)., Results: Of the 1000 randomized patients, 982 were included (median age, 65 [IQR, 55-73] years; 305 [31%] women) and primary outcome data were available for 971 (491 in the 12 mg of dexamethasone group and 480 in the 6 mg of dexamethasone group). The median number of days alive without life support was 22.0 days (IQR, 6.0-28.0 days) in the 12 mg of dexamethasone group and 20.5 days (IQR, 4.0-28.0 days) in the 6 mg of dexamethasone group (adjusted mean difference, 1.3 days [95% CI, 0-2.6 days]; P = .07). Mortality at 28 days was 27.1% in the 12 mg of dexamethasone group vs 32.3% in the 6 mg of dexamethasone group (adjusted relative risk, 0.86 [99% CI, 0.68-1.08]). Mortality at 90 days was 32.0% in the 12 mg of dexamethasone group vs 37.7% in the 6 mg of dexamethasone group (adjusted relative risk, 0.87 [99% CI, 0.70-1.07]). Serious adverse reactions, including septic shock and invasive fungal infections, occurred in 11.3% in the 12 mg of dexamethasone group vs 13.4% in the 6 mg of dexamethasone group (adjusted relative risk, 0.83 [99% CI, 0.54-1.29])., Conclusions and Relevance: Among patients with COVID-19 and severe hypoxemia, 12 mg/d of dexamethasone compared with 6 mg/d of dexamethasone did not result in statistically significantly more days alive without life support at 28 days. However, the trial may have been underpowered to identify a significant difference., Trial Registration: ClinicalTrials.gov Identifier: NCT04509973 and ctri.nic.in Identifier: CTRI/2020/10/028731.

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results